-
Mashup Score: 2ERBB4-mediated signaling is a mediator of resistance to BTK and PI3K inhibitors in B cell lymphoid neoplasms - 1 year(s) ago
BTK and PI3K inhibitors are among the drugs approved for the treatment of patients with lymphoid neoplasms. Although active, their ability to lead as single agents to long-lasting complete remission is rather limited especially in the lymphoma setting. This indicates that tumor cells often develop resistance to the drugs. Here, we show that the overexpression of ERBB4 and its ligands represents a…
Source: bioRxivCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 1
Blood Podcast – Season 4, Episode 22 | Blood | American Society of Hematology Using MRD to guide CLL treatment intensity, donor NK cells boost immune reconstitution after haplo-BMT, and EZH2 drives retinoic acid resistance in variant APL In this week’s episode we discuss encouraging results of a phase 2 study using a sequential ibrutinib-venetoclax treatment approach driven by…
Source: ashpublications.orgCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
New podcast episode! Topics include using #MRD to guide #CLL treatment intensity, donor NK cells boost immune reconstitution after haplo-BMT, and #EZH2 drives retinoic acid resistance in variant APL https://t.co/yhvs56umG3 https://t.co/0Pw1Ih6dyW
-
-
Mashup Score: 0PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer - 1 year(s) ago
Abstract. The immunosuppressive tumor microenvironment in some cancer types, such as luminal breast cancer, supports tumor growth and limits therapeutic efficacy. Identifying approaches to induce an immunostimulatory environment could help improve cancer treatment. Here, we demonstrate that inhibition of cancer-intrinsic EZH2 promotes antitumor immunity in estrogen receptor a-positive (ERa+)…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
#ICYMI: Inhibition of #EZH2 activates a type I IFN-STAT2 signaling axis to stimulate antitumor immunity and therapy responsiveness in luminal #BreastCancer, by Hong et al. https://t.co/YDl0v2AeL0 @UTHealthHouston https://t.co/ON1mQEkijA
-
-
Mashup Score: 0PRC2-mediated epigenetic suppression of type I IFN-STAT2 signaling impairs antitumor immunity in luminal breast cancer - 1 year(s) ago
Abstract. The immunosuppressive tumor microenvironment in some cancer types, such as luminal breast cancer, supports tumor growth and limits therapeutic efficacy. Identifying approaches to induce an immunostimulatory environment could help improve cancer treatment. Here, we demonstrate that inhibition of cancer-intrinsic EZH2 promotes antitumor immunity in estrogen receptor a-positive (ERa+)…
Categories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Inhibition of #EZH2 activates a type I IFN-STAT2 signaling axis to stimulate antitumor immunity and therapy responsiveness in luminal #BreastCancer, by Hong et al. https://t.co/CnZiJFI6hx @UTHealthHouston https://t.co/R2LY72Bmwg
-
-
Mashup Score: 10Polycomb Directed Cell Fate Decisions in Development and Cancer - 2 year(s) ago
The polycomb group (PcG) proteins are a subset of transcription regulators highly conserved throughout evolution. Their principal role is to epigenetically modify chromatin landscapes and control the expression of master transcriptional programs to determine cellular identity. The two mayor PcG protein complexes that have been identified in mammals to date are Polycomb Repressive Complex 1 (PRC1)…
Source: MDPICategories: Hem/Oncs, Latest HeadlinesTweet-
New review from @beatrizgerfalc @PCF_Science @CSCancerCare @Epigenomes Thanks to the editors @lluismorey @DiCroceLab #EZH2 #CellFate Polycomb Directed Cell Fate Decisions in Development and Cancer https://t.co/nmENiGT5CP
-
-
Mashup Score: 0Pamela J. Sung, MD @RoswellPark #ASH21 #AML #EZH2 #Canc - 2 year(s) ago
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregul
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FLT3 Inhibition Downregulates EZH2 in AML Pamela J. Sung, MD @RoswellPark #ASH21 #AML #EZH2 #Cancer #Research https://t.co/xnfNt1jUx1 https://t.co/XmLT2KPzOR
-
-
Mashup Score: 2Podcast - Pamela J. Sung, MD @RoswellPark #ASH21 #AML # - 2 year(s) ago
Pamela J. Sung, MD from the Department of Medicine, Roswell Park Comprehensive Cancer Center speaks about ASH 2021 Abstract – 785 FLT3 Inhibition Downregul
Source: www.oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Podcast - FLT3 Inhibition Downregulates EZH2 in AML Pamela J. Sung, MD @RoswellPark #ASH21 #AML #EZH2 #Cancer #Research Link to Audio: https://t.co/4IWXeg62Rr https://t.co/MXVSpGyL95
-
-
Mashup Score: 13Dynamic prostate cancer transcriptome analysis delineates the trajectory to disease progression - Nature Communications - 2 year(s) ago
Transcriptional changes during prostate cancer progression are not yet fully understood. Here, the authors integrate a transcriptomics atlas of prostate cancer and validate it with preclinical models and single-cell RNA-seq, revealing the role of EZH2 and macrophage polarisation in tumour progression.
Source: Nature CommunicationsCategories: General Medicine News, Latest HeadlinesTweet-
Transcriptome atlas of #ProstateCancer and cell lines, patient-derived #xenografts and #scRNAseq reveal roles of #EZH2 and macrophage polarisation #CancerResearch by @MBolisDr @JTheurillat @DidyBossi @VallergaArianna @Danida0 @LauraDiRitoMN @NatResCancer https://t.co/i3VWWQnC0Q https://t.co/nnmvWhHROr
-
-
Mashup Score: 4
Learn more about applying for Postdoctoral Scientist – Cancer Institute, Ellis Lab at Cedars-Sinai
Source: jobs.cedars-sinai.eduCategories: Hem/Oncs, Latest HeadlinesTweet-
We are looking for a motivated #postdoc to use proteomics and functional genomics to understand the role of #EZH2 in #prostatecancer lineage plasticity @PCF_Science @epicancerpapers @AEpiA https://t.co/o5QTsyxvAD
-
-
Mashup Score: 9Metastases arrive at other organs via bone - 3 year(s) ago
Zhang et al. show that, in mouse models, bone metastases can seed metastases in other organs and that this is driven by EZH2-mediated epigenetic reprogramming to promote stem cell-like features.
Source: Nature Reviews CancerCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
NEW #ResearchHighlight! Zhang et al. show that, in mouse models, #BoneMetastases can seed #Metastases in other organs and that this is driven by #EZH2-mediated epigenetic reprogramming to promote stem cell-like features. 📯 https://t.co/NiXRxKxCKT @natrescancer @BCMFromtheLabs https://t.co/3vIIC0YKQU
-
Contributing to show that #epigenetic reprogramming by DNA #demethylating agents or #EZH2 inhibitors overcome #ERBB4 mediated resistance to #BTK and #PI3K inhibitors in #lymphoma, great work led by @frbertoni @IOR_Bellinzona now at @biorxivpreprint https://t.co/Yi2JA1eVGn https://t.co/9XgSCQv8xL